Completed PHASE2 INTERVENTIONAL 2-arm NCT04701333

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss (LISTA)

Sponsor: Stanford University

Updated 10 times since 2021 Last updated: Jan 19, 2024 Started: Apr 1, 2021 Primary completion: Jun 24, 2022 Completion: Mar 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lactation Suppressed and is currently completed. Stanford University leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2
May 2023 — Mar 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2023 — May 2023 [monthly]

Active Not Recruiting PHASE2

▶ Show 5 earlier versions

Nov 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Mar 2021 — Jun 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2021 — Mar 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States